

Manuscript no. HAEMATOL/2011/053611 entitled “Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia”

Authors: Kim F. Pearce, Stephanie J. Lee, Michael Haagenson, Effie W. Petersdorf, Jean Norden, Matthew P. Collin, John P. Klein, Stephen R. Spellman, Shelagh A. Lowerson, Stella Davies, Anne M. Dickinson

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:

- Kim Pearce, Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, k.f.pearce@ncl.ac.uk
- Stephanie Lee, Fred Hutchinson Cancer Research Center, Seattle, USA, sjlee@fhcrc.org
- Michael Haagenson, Center for International Blood and Marrow Transplant Research, Minneapolis, USA, mhaagens@NMDP.ORG
- Effie Petersdorf, Fred Hutchinson Cancer Research Center, Seattle, USA, epetersd@fhcrc.org
- Jean Norden, Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, jean.norden@ncl.ac.uk
- Matthew Collin, Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, matthew.collin@ncl.ac.uk
- John Klein, Medical College of Wisconsin, Milwaukee, USA, klein@mcw.edu
- Stephen R. Spellman, Center for International Blood and Marrow Transplant Research, Minneapolis, USA, sspellma@NMDP.ORG
- Shelagh Lowerson, Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, shelagh.lowerson@ncl.ac.uk
- Stella Davies, Cincinnati Children’s Hospital, Cincinnati, USA, stella.davies@cchmc.org
- Anne M. Dickinson, Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, a.m.dickinson@ncl.ac.uk

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html): “*Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship*”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Kim Pearce, Stephanie Lee, Michael Haagenson, Jean Norden, Stephen R. Spellman, Anne M. Dickinson

3) Design & Methods. The following authors were responsible for specific investigations (please detail):

- Kim Pearce proposed and performed all statistical analyses
- Michael Haagenson provided and coded the data set
- Stephanie Lee interpreted some results
- Jean Norden typed of the genes
- Anne Dickinson designed research and interpreted data
- John Klein gave some statistical recommendations for some of the analysis
- Stephen Spellman designed research and interpreted results
- Stella Davies and Effie Petersdorf interpreted some of the results

- Shelagh Lowerson was data base manager
- Matthew Collin was lead clinician and provided some interpretations

4) **Results.** The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):

- Kim Pearce performed all statistical analyses and was involved in the generation of every figure and table.
- Jean Norden provided rs numbers in Table 1 and minor allele frequencies in Table 3.
- Michael Haagensohn made some contribution to Table 1.

5) **Writing the manuscript.** The following authors were responsible for writing the manuscript:

- Kim Pearce wrote up the results of the statistical analyses
- Stephanie Lee, Jean Norden, Anne Dickinson, Stephen Spellman, Stella Davies, Effie Petersdorf and Matthew Collin contributed to the discussion.

6) **Contributors Listed in Acknowledgments:**

The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan Biovitrum; THERAKOS, Inc.; and Wellpoint, Inc.